Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Salicylic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 1.00 |
| ▸ | HPGD | P15428 | 6/20 | 1.00 |
| ▸ | CA12 | O43570 | 3/20 | 1.00 |
| ▸ | CA1 | P00915 | 3/20 | 1.00 |
| ▸ | CA2 | P00918 | 3/20 | 1.00 |
| ▸ | CA7 | P43166 | 3/20 | 1.00 |
| ▸ | CA9 | Q16790 | 3/20 | 1.00 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 1.00 |
| ▸ | HMGB1 | P09429 | 1/20 | 1.00 |
| ▸ | CA4 | P22748 | 1/20 | 1.00 |
| ▸ | CA6 | P23280 | 1/20 | 1.00 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.68 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.61 |
| ▸ | MAPT | P10636 | 2/20 | 0.61 |
| ▸ | TSHR | P16473 | 2/20 | 0.61 |
| ▸ | G6PD | P11413 | 1/20 | 0.60 |
| ▸ | CASP7 | P55210 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Salicylic Acid SCHEMBL17156443 | 1.00 | ALDH1A1 (1.00) | ALDH1A1KDM4EHPGDCA12CA1 | |
| Salicylic Acid SCHEMBL8433746 | 1.00 | ALDH1A1 (1.00) | ALDH1A1KDM4EHPGDCA12CA1 | |
| Salicylic Acid SCHEMBL29360246 | 1.00 | ALDH1A1 (1.00) | ALDH1A1KDM4EHPGDCA12CA1 | |
| Salicylic Acid SCHEMBL29606432 | 1.00 | ALDH1A1 (1.00) | ALDH1A1KDM4EHPGDCA12CA1 | |
| Salicylic Acid SCHEMBL1967 | 1.00 | ALDH1A1 (1.00) | ALDH1A1KDM4EHPGDCA12CA1 | |
| Salicylic Acid SCHEMBL29362663 | 1.00 | ALDH1A1 (1.00) | ALDH1A1KDM4EHPGDCA12CA1 | |
| Salicylic Acid SCHEMBL9982 | 0.97 | ALDH1A1 (0.95) | ALDH1A1KDM4EHPGDCA12CA1 | |
| Salicylic Acid SCHEMBL299754 | 0.97 | ALDH1A1 (0.95) | ALDH1A1KDM4EHPGDCA12CA1 | |
| Salicylic Acid SCHEMBL546853 | 0.97 | ALDH1A1 (0.95) | ALDH1A1KDM4EHPGDCA12CA1 | |
| Salicylic Acid SCHEMBL12477692 | 0.97 | ALDH1A1 (0.95) | ALDH1A1KDM4EHPGDCA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220062226-A1 | UROLITHIN A AND A COMPOSITION CONTAINING SAME FOR EXTERNAL USE IN INFLAMMATIONS OF VARIOUS ETIOLOGIES | MICROBIOTA MED. SP. Z O.O. (PL) | 2022-03-03 | — | — | US | claimed |
| EP-3886808-A1 | UROLITHIN A AND A COMPOSITION CONTAINING SAME FOR EXTERNAL USE IN INFLAMMATIONS OF VARIOUS ETIOLOGIES | Warszawski Uniwersytet Medyczny (PL) | 2021-10-06 | — | — | EP | claimed |
| WO-2020110089-A1 | UROLITHIN A AND A COMPOSITION CONTAINING SAME FOR EXTERNAL USE IN INFLAMMATIONS OF VARIOUS ETIOLOGIES | WARSZAWSKI UNIWERSYTET MEDYCZNY (PL) | 2020-06-04 | — | — | WO | claimed |
| EP-2376420-B1 | USE OF AN ESTER IN A BINDER SYSTEM | BOSCH GMBH ROBERT (DE) | 2018-11-14 | — | — | EP | claimed |
| EP-2630947-B1 | Stable perfume, waterproof cosmetic preparation | BEIERSDORF AG (DE) | 2018-07-25 | — | — | EP | claimed |
| EP-1907377-B1 | A PROCESS FOR THE PREPARATION OF ALMOTRIPTAN | MATRIX LAB LTD (IN) | 2013-04-24 | — | — | EP | claimed |
| EP-2376420-A1 | METHOD FOR PRODUCING AN ESTER AND BINDER SYSTEM | Robert Bosch GmbH (DE) | 2011-10-19 | — | — | EP | claimed |
| WO-2010072503-A1 | METHOD FOR PRODUCING AN ESTER AND BINDER SYSTEM | ROBERT BOSCH GMBH (DE) | 2010-07-01 | — | — | WO | claimed |
| US-11970637-B2 | Block polymer, polymer composition, and adhesive | ENEOS MATERIALS CORPORATION (JP) | 2024-04-30 | — | — | US | disclosed |
| EP-4352037-A1 | CARBOXYLIC ACID LOADED SALT CARRIER AND THE METHOD FOR PRODUCING THEREOF | BRENDLER, Lucas (DE) | 2024-04-17 | — | — | EP | disclosed |
| WO-2022258807-A1 | CARBOXYLIC ACID LOADED SALT CARRIER AND THE METHOD FOR PRODUCING THEREOF | BRENDLER LUCAS (DE) | 2022-12-15 | — | — | WO | disclosed |
| US-20220062226-A1 | UROLITHIN A AND A COMPOSITION CONTAINING SAME FOR EXTERNAL USE IN INFLAMMATIONS OF VARIOUS ETIOLOGIES | MICROBIOTA MED. SP. Z O.O. (PL) | 2022-03-03 | — | — | US | disclosed |
| EP-3886808-A1 | UROLITHIN A AND A COMPOSITION CONTAINING SAME FOR EXTERNAL USE IN INFLAMMATIONS OF VARIOUS ETIOLOGIES | Warszawski Uniwersytet Medyczny (PL) | 2021-10-06 | — | — | EP | disclosed |
| EP-3749281-A1 | PERFUME COMPLEX AND SCENTED WATER COMPOSITION | Expressions Parfumees (FR) | 2020-12-16 | — | — | EP | disclosed |
| WO-1999027351-A1 | BIOLUMINESCENT BIOREPORTER INTEGRATED CIRCUIT | LOCKHEED MARTIN ENERGY RESEARCH CORPORATION (US) | 1999-06-03 | — | — | WO | disclosed |
| EP-0748365-A4 | OVERBASED ALKYL OXY BENZENE SULFONATES AS DETERGENTS | CHEVRON CHEM CO (US) | 1998-12-16 | — | — | EP | disclosed |
| EP-0748365-A1 | OVERBASED ALKYL OXY BENZENE SULFONATES AS DETERGENTS | CHEVRON CHEMICAL COMPANY (US) | 1996-12-18 | — | — | EP | disclosed |
| WO-1996020265-A1 | OVERBASED ALKYL OXY BENZENE SULFONATES AS DETERGENTS | CHEVRON CHEMICAL COMPANY (US) | 1996-07-04 | — | — | WO | disclosed |
| US-5421983-A | Used for performing potentiometric determination of chloride ions | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1995-06-06 | — | — | US | disclosed |
| US-4406896-A | ANTIBIOTICS, ACIDS, HYDROXY | MERCK & CO., INC. (US) | 1983-09-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220062226-A1 | UROLITHIN A AND A COMPOSITION CONTAINING SAME FOR EXTERNAL USE IN INFLAMMATIONS OF VARIOUS ETIOLOGIES | UTS2R, UPP1, UACA | ALDH1A1 1438/4885KDM4E 4284/4885HPGD 1273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.